<DOC>
	<DOC>NCT00149214</DOC>
	<brief_summary>An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary, operable breast cancer (T2-T4/N0-2/M0).</brief_summary>
	<brief_title>Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirmed diagnosis of primary early breast cancer, tumor size greater than or equal to 2 centimeters (cm), of Stages T2T4/N02. Performance status 02 Eastern Cooperative Oncology Group (ECOG). Adequate organ function (bone marrow, hepatic, renal, cardiac). Prior anthracyclines as part of prior anticancer therapy. Concurrent antitumor therapy. Second primary malignancy. Serious concomitant systemic disorder. Preexisting sensorial or motor neuropathy Grade 1.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>